Navigation Links
Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
Date:2/24/2011

THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA (denosumab) to Zometa® (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published in The Lancet, met its primary and secondary endpoints and demonstrated XGEVA's superiority compared to Zometa in preventing SREs.

XGEVA was approved by the U.S. Food and Drug Administration (FDA) on Nov. 18, 2010 for the prevention of SREs in patients with bone metastases from solid tumors, including prostate cancer.  XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.  XGEVA, the first and only FDA-approved RANK Ligand inhibitor, is the first new treatment for advanced cancer patients with bone metastases in nearly a decade.  

"Bone metastases represent a significant risk for advanced prostate cancer patients due to the potential for serious bone complications such as fracture and spinal cord compression," said Karim Fizazi, M.D., Ph.D., head of the department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France. "The results of this study show that XGEVA prevents these serious bone complications more effectively than Zometa without the requirement of intravenous infusion and without the need for dose adjustment for renal function.  XGEVA represents an important new treatment option for advanced prostate cancer patients with bone metastases."

Bone metastases, the spread of cancer to the bones, are a serious concern for patients with advanced cancer and present a considerable burden to the healthcare system. Weakened bones due to metastases can lead to fractures and compression of the spinal cord and necessi
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... Vittamed Corporation , a neurodiagnostics medical device company based in ... (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd ... " Teo Forcht Dagi is an experienced leader ... capital," said Remis Bistras , President and CEO of ... and entrepreneurial expertise to our Board." Dr. Dagi ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:9/1/2014)... (PRWEB) September 01, 2014 "Women struggle ... These hormonal daily changes begin as early as 15, ... their lives negotiating the ups and downs of hormone ... thin or even healthy sizes seems to rage against ... As a woman in her 40's begin to face ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... The Outlier Series announced the next short e-Book ... one of the exceptional women featured in the series’ ... . The title of the upcoming mini e-Book is ... . McClendon is currently a full-time physician’s assistant, and ... WeTV show, Raising Sextuplets. , Jenny was chosen as ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as ... can have devastating effects on those who develop it. ... they are not produced by electrical anomalies in the ... estimated that the numbers of persons suffering PNES may ... , Dr. Lorna Myers, Director of the Northeast ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... CINCINNATI, July 28 LCA-Vision Inc. (Nasdaq: LCAV ... Lasik Plus ((R)) brand, today announced financial and operating results for ... , Second Quarter 2009 Operational and Financial Results ... , Revenue was $31.7 million compared with ...
... , , , MINNEAPOLIS, July ... and marketer of state-of-the-art cardiac surgery products, announced today that it ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , ... Focus on Healthcare Conference at the Millennium Broadway Hotel in New ...
... , GLEN ROCK, N.J., July 28 ... of Fingertip Formulary Accounts((R)), a state-of-the art web-based platform ... data and resources at an account level. The ... now provides immediate, real-time integrated provider-level data that includes ...
... , , DENVER, ... caregiver workflow in healthcare environments, today announced that Alegent ... ThinIdentity solution throughout its healthcare system. The first installation ... Iowa. A 278-bed facility, Mercy Hospital has over 1,000 ...
... July 28 According to a new market,research report, ,Drug-Device ... the total drug-device,combination market is expected to be worth US$18.54 ... for nearly 30.9% of the total revenues.,The global market is ... 2014. , Browse 144 market data ...
... ... first analog frame grabber for the National Instruments CompactRIO embedded real-time platform at the ... NIWeek the world,s leading graphical system design conference and exhibition hosted by National Instruments. ... Irvine, CA ...
Cached Medicine News:Health News:LCA-Vision Reports Second Quarter Financial Results 2Health News:LCA-Vision Reports Second Quarter Financial Results 3Health News:LCA-Vision Reports Second Quarter Financial Results 4Health News:LCA-Vision Reports Second Quarter Financial Results 5Health News:LCA-Vision Reports Second Quarter Financial Results 6Health News:LCA-Vision Reports Second Quarter Financial Results 7Health News:LCA-Vision Reports Second Quarter Financial Results 8Health News:LCA-Vision Reports Second Quarter Financial Results 9Health News:LCA-Vision Reports Second Quarter Financial Results 10Health News:LCA-Vision Reports Second Quarter Financial Results 11Health News:LCA-Vision Reports Second Quarter Financial Results 12Health News:LCA-Vision Reports Second Quarter Financial Results 13Health News:LCA-Vision Reports Second Quarter Financial Results 14Health News:ATS Medical to Participate at Upcoming Investor Conferences 2Health News:Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... (DHEA-S) is the sulfate ester of DHEA, ... conversion of DHEA in adrenal and extradrenal ... secreted by the adrenal cortex, and is ... DHEA possesses relatively weak androgenic activity, which ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: